These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 35122335)

  • 61. Dupilumab use in atopic dermatitis and beyond in skin diseases.
    Fourzali K; Golpanian RS; Yosipovitch G
    Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety of dupilumab in patients with atopic dermatitis: expert opinion.
    Francuzik W; Alexiou A; Worm M
    Expert Opin Drug Saf; 2021 Sep; 20(9):997-1004. PubMed ID: 34114910
    [No Abstract]   [Full Text] [Related]  

  • 65. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
    Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
    Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Salman A; Apti Sengun Ö; Aktas M; Taşkapan O
    Dermatol Ther; 2022 Jan; 35(1):e15192. PubMed ID: 34743366
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
    Agnihotri G; Shi K; Lio PA
    Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Paller AS; Simpson EL; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Soong W; Gonzalez ME; Schneider LC; Sidbury R; Lockshin B; Meltzer S; Wang Z; Mannent LP; Amin N; Sun Y; Laws E; Akinlade B; Dillon M; Kosloski MP; Kamal MA; Dubost-Brama A; Patel N; Weinreich DM; Yancopoulos GD; O'Malley JT; Bansal A;
    Lancet; 2022 Sep; 400(10356):908-919. PubMed ID: 36116481
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An updated reappraisal of dupilumab in children and adolescents with moderate-severe atopic dermatitis.
    Ciprandi G; Licari A; Tosca MA; Miraglia Del Giudice M; Belloni Fortina A; Marseglia GL
    Pediatr Allergy Immunol; 2024 Jun; 35(6):e14181. PubMed ID: 38934228
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience.
    Gelato F; Mastorino L; Quaglino P; Cavaliere G; Ortoncelli M; Ribero S
    Dermatitis; 2023; 34(5):445-447. PubMed ID: 36917522
    [No Abstract]   [Full Text] [Related]  

  • 73. Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases.
    Kychygina A; Cassagne M; Tauber M; Galiacy S; Paul C; Fournié P; Simon M
    Clin Rev Allergy Immunol; 2022 Jun; 62(3):519-533. PubMed ID: 35275334
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
    Paller AS; Siegfried EC; Thaçi D; Wollenberg A; Cork MJ; Arkwright PD; Gooderham M; Beck LA; Boguniewicz M; Sher L; Weisman J; O'Malley JT; Patel N; Hardin M; Graham NMH; Ruddy M; Sun X; Davis JD; Kamal MA; Khokhar FA; Weinreich DM; Yancopoulos GD; Beazley B; Bansal A; Shumel B
    J Am Acad Dermatol; 2020 Nov; 83(5):1282-1293. PubMed ID: 32574587
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A review of dupilumab in the treatment of atopic diseases.
    Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
    Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A study into the drug dupilumab in Japanese adults with moderate-to-severe atopic dermatitis.
    Br J Dermatol; 2020 Jul; 183(1):e4-e30. PubMed ID: 32613649
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children.
    Wang M; Gao XH; Zhang L
    Drug Des Devel Ther; 2024; 18():941-951. PubMed ID: 38560522
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
    D'Erme AM; Romanelli M; Chiricozzi A
    Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study.
    Yang DY; Li L; Lu T; Jing WW; Liu X; Li XL
    Arch Dermatol Res; 2023 Apr; 315(3):467-472. PubMed ID: 35989340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.